AL2846
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.AL2846 is one of 11 small molecule programs targeting Differentiated Thyroid Carcinoma. It is currently in Phase 3.
1
Indications
9
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Differentiated Thyroid Carcinoma
#DrugCompanyPhaseTrials
1Mekinist
NovartisPhase 3
Tafinlar
NovartisPhase 3
Cotellic
RochePhase 2
Anlotinib Hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 2
AL2846
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Nexavar
BayerPreclinical
Radioactive Iodine Therapy
AstraZenecaPhase 2
Tirosint
IInstitut Jerome Lejeune
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Differentiated Thyroid Carcinoma1 trial
Thyroid Cancer1 trial
Neurofibromatosis1 trial
4 more indications
Patients With Advanced Solid Tumors1 trial
Ovarian Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AL2846. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details